Affinity Capital Advisors, LLC Esperion Therapeutics, Inc. Transaction History
Affinity Capital Advisors, LLC
- $526 Million
- Q1 2025
A detailed history of Affinity Capital Advisors, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Affinity Capital Advisors, LLC holds 10,000 shares of ESPR stock, worth $11,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$11,200% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$15.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$12.9 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$12.2 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$10.9 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$7.76 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $74.5M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...